Alternate-Day Buprenorphine. Phase V - 6 - Tabular View

Tracking Information

First Received Date ^ICMJE

September 20, 1999

Last Updated Date

June 23, 2005

Start Date ^ICMJE

February 1993

Primary Completion Date

Current Primary Outcome Measures ^ICMJE

Drug use
Opioid withdrawal
Subjective dose estimate
Drug effect characteristics: ARCI
Physiological changes in: pupil diameter
Physiological changes in: blood pressure
Physiological changes in: heart rate
Physiological changes in: respiration
Physiological changes in: bup plasma levels

Original Primary Outcome Measures ^ICMJE

Same as current

Change History

Complete list of historical versions of study NCT00000224 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Original Secondary Outcome Measures ^ICMJE

Descriptive Information

Brief Title ^ICMJE

Alternate-Day Buprenorphine. Phase V - 6

Official Title ^ICMJE

Alternate-Day Buprenorphine. Phase V

Brief Summary

The purpose of this study is to evaluate buprenorphine blockade challenge.

Detailed Description

Study Phase

Phase I

Study Type ^ICMJE

Interventional

Study Design ^ICMJE

Treatment, Double-Blind, Placebo Control, Crossover Assignment

Condition ^ICMJE

Opioid-Related Disorders

Intervention ^ICMJE

Drug: Buprenorphine

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

Completion Date

Primary Completion Date

Eligibility Criteria ^ICMJE

Please contact site for information.

Gender

Both

Ages

30 Years to 49 Years

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

United States

Administrative Information

NCT ID ^ICMJE

NCT00000224

Responsible Party

Study ID Numbers ^ICMJE

NIDA-06969-6, R01-06969-6

Study Sponsor ^ICMJE

National Institute on Drug Abuse (NIDA)

Collaborators ^ICMJE

University of Vermont

Investigators ^ICMJE

Principal Investigator:

Warren Bickel, Ph.D.

University of Vermont

Information Provided By

National Institute on Drug Abuse (NIDA)

Verification Date

April 1996

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP